MedTrace Logo

COVID-19 Vaccination in Patients With Rheumatic Diseases

NCT04845997 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2023-02-01

No results posted yet for this study

Summary

The Argentine Society of Rheumatology (SAR) set out to develop a national register of patients with rheumatic diseases who have received a SARS-CoV-2 vaccine in order to assess their efficacy and safety in this population.

Conditions

  • Rheumatic Diseases

Interventions

BIOLOGICAL

COVID-19 Vaccine

Patients with rheumatic diseases who have been vaccinated for COVID-19

Sponsors & Collaborators

  • Sociedad Argentina de Reumatologia

    lead OTHER

Principal Investigators

  • Carolina Isnardi, MD · Unidad de Investigación Sociedad Argentina Reumatología

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2023-06-30
Completion
2023-12-31

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04845997 on ClinicalTrials.gov